SIGLEC15 and lung adenocarcinoma: Interestingly, studies have shown that the expression of SIGLEC-15 and PD-L1 can be mutually exclusive in certain tumors, including lung adenocarcinoma and bladder cancer, indicating that these markers might serve different immunosuppressive mechanisms [11,12].